Therapeutic Asset Ratings
205 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Evomela
Mantle Cell Lymphoma
Ruijin Hospital
P3
B
(60)
Azacitidine
Myeloid Sarcoma
Ruijin Hospital
P2
B
(60)
Zanubrutinib
Large B-Cell Lymphoma (LBCL)
Ruijin Hospital
P2
B
(60)
BMS-986345
Chronic Lymphocytic Leukemia
Ruijin Hospital
P3
B
(58)
cc-5013
Large B-cell Lymphoma
Ruijin Hospital
P3
B
(58)
5-azacytidine
PTCL
Ruijin Hospital
P2
B
(58)
Apg-2575
DLBCL - Diffuse Large B Cell Lymphoma
Ruijin Hospital
P2
B
(58)
Capecitabine
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Ruijin Hospital
P2
B
(58)
Jwcar029
DLBCL - Diffuse Large B Cell Lymphoma
Ruijin Hospital
P2
B
(58)
Obutinib
Diffuse Large B Cell Lymphoma (DLBCL)
Ruijin Hospital
P2
B
(58)
Polatuzumab Vedotin
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Ruijin Hospital
P2
B
(58)
Selinexor
Central Nervous System Lymphoma
Ruijin Hospital
P2
B
(58)
Tislelizumab
Peripheral T Cell Lymphoma
Ruijin Hospital
P2
B
(58)
Toripalimab
Pancreatic Neoplasm
Ruijin Hospital
P2
B
(58)
Zanubrutinib
CNS Lymphoma
Ruijin Hospital
P2
B
(58)
Zeprumetostat
PTCL
Ruijin Hospital
P2
B
(58)
Tegodor
Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
P2
B
(57)
Tegodor
Pancreatic Neoplasms
Ruijin Hospital
P2
B
(57)
BMS-986345
Follicular Lymphoma
Ruijin Hospital
P3
B
(56)
Duvelisib
Follicular Lymphoma
Ruijin Hospital
P3
B
(56)
ag-120
Myelodysplastic Syndromes
Ruijin Hospital
P2
B
(56)
Zanubrutinib
Large B-cell Lymphoma
Ruijin Hospital
P2
CCC
(55)
Avastinib
MDS
Ruijin Hospital
P2/3
CCC
(55)
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Parkinson Disease
Ruijin Hospital
P3
CCC
(54)
BMS-986345
Marginal Zone Lymphoma
Ruijin Hospital
P3
CCC
(54)
Showing 51 to 75 of 205 assets
Previous
Page 3 of 9
Next